Aspirin Per Se (i.e., 2-(acetyloxy)benozic Acid) Patents (Class 514/165)
  • Patent number: 10391080
    Abstract: Methods of treating cancer, including PAR-4 implicated cancers or renal cell carcinoma, using ketorolac are disclosed herein. Ketorolac can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: August 27, 2019
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Patent number: 10391096
    Abstract: A method for treating thrombotic disorders using a composition containing quercetin, together with one or more of vitamin B3, vitamin C, and folic acid. Also disclosed is a method of improving the efficacy of a blood thinning medication by co-administering a composition containing quercetin, together with one or more of vitamin B3, vitamin C, and folic acid to a subject being treated with a blood thinning medication.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: August 27, 2019
    Assignee: Quercegen Pharmaceuticals LLC
    Inventor: Thomas Christian Lines
  • Patent number: 10238622
    Abstract: The invention provides methods of treatment that prevent the onset of Mesial temporal lobe epilepsy (TLE) in a subject, or which reduce the severity of TLE in a subject, by administering a NKCC1 inhibitor to the subject after the subject has suffered from an insult known to precipitate TLE.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: March 26, 2019
    Inventors: Wolfgang S. Mueller, John A. Connor, Steven Peterson, Denis Bragin
  • Patent number: 10124005
    Abstract: Migraine is a multi-symptom disease involving pain; histamine triggers; and nausea with or without vomiting. Current over-the-counter medications focus only on treating pain. This invention involves treating other common triggers and symptoms as well as pain. Acetaminophen and caffeine are already being used but the addition of meclizine is what makes this medication my invention. The addition of meclizine covers the other symptoms that make migraine sufferers miserable which is nausea/vomiting and treats the possible histamine mediated trigger of migraines because it has antihistaminic properties. As a migraine sufferer myself, I experience all of these symptoms and would very much like to have everything I need to cover these debilitating symptoms in one medication hence my invention.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: November 13, 2018
    Inventor: Lisa Josette Myslinski
  • Patent number: 10103225
    Abstract: Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: October 16, 2018
    Inventors: Michelle Reillo, Marian E. Washington
  • Patent number: 10084044
    Abstract: Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: September 25, 2018
    Inventors: Michelle Reillo, Marian E. Washington
  • Patent number: 10000735
    Abstract: The present invention relates to a medium composition containing an Ecklonia cava extract for dedifferentiating an induced pluripotent stem cell. Also, the present invention relates to a method for differentiating an induced pluripotent stem cell, produced by using the medium composition into a neuron. When using the medium composition according to the present invention, induced pluripotent stem cells using mesenchymal stem cells can be produced efficiently, and the pluripotent stem cells which have been produced can be useful as a cell treatment agent by being capable of being differentiated into neurons.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: June 19, 2018
    Assignee: BBHC CO., LTD.
    Inventors: Sang Yeon Lee, Won Ju Jung, Ho Bin Kim, Min Sun Oh, Kye Ho Lee
  • Patent number: 9974763
    Abstract: A composition for treating Neurodegenerative Diseases with Parkinsonian Syndromes in a subject in need thereof, wherein the composition includes an effective amount of a modulator of a chloride transporter.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: May 22, 2018
    Assignees: B&A THERAPEUTICS, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AUX MARSEILLE, UNIVERSITE DE NANTES
    Inventors: Yehezkel Ben-Ari, Nathalie Dehorter, Philippe Damier, Constance Hammond
  • Patent number: 9956187
    Abstract: The invention relates to dezocine compositions and uses thereof. Specifically, the invention relates to dezocine compositions, including nano-dezocine compositions and methods for preventing or treating opioid receptor associated diseases, including neuropathic pain; addiction, such as opioid or cocaine addiction; and depression.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: May 1, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Renyu Liu, Geoffrey Krug, Feixiang Wu, Julie Blendy
  • Patent number: 9896411
    Abstract: Methods of making cocrystal compositions of metoprolol and dabigatran bases with enantiomers of theanine.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: February 20, 2018
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Patent number: 9839612
    Abstract: Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: December 12, 2017
    Inventors: Michelle Reillo, Marian E. Washington
  • Patent number: 9750725
    Abstract: Compounds of formula I and their metabolites are potent mediators of an inflammatory response: where a, b, c, d, e, f, V, W, X, Y, Ra, Ra?, Rb, Rb?, Rc, and Rc? are defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: September 5, 2017
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Bruce A. Freeman, Francisco J. Schopfer
  • Patent number: 9676715
    Abstract: Novel bis-indolic derivatives, processes for their preparation, and their potential use as new antibacterial drugs.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: June 13, 2017
    Assignee: UNIVERSITE JOSEPH FOURIER
    Inventors: Jean-Noël Denis, Marcelle Claude Jolivalt, Louis Maurin Max Maurin, Matthieu Jeanty
  • Patent number: 9351980
    Abstract: The invention relates to the use of di-aspirin (bis(2-carboxyphenyl)succinate) and its derivatives in the treatment of colon and colorectal cancer. It also relates to novel derivatives of di-aspirin and to a method of synthesis of the di-aspirin and its derivatives.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: May 31, 2016
    Assignee: The University of Wolverhampton
    Inventors: Christopher John Perry, Iain Douglas Nicholl
  • Patent number: 9345678
    Abstract: Embodiments described herein are directed to prostanoid (IP) receptor agonist compounds, including cicaprost and certain prodrugs, and methods of preparation and use for the same. Certain embodiments are directed to the use of cicaprost and certain prodrugs in the treatment of topical and ocular conditions.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: May 24, 2016
    Assignee: ALLERGAN, INC.
    Inventors: Jenny W. Wang, David F. Woodward, Neil J. Poloso, Julia Herrmann
  • Patent number: 9321785
    Abstract: The present invention relates to a method of ameliorating the drawbacks of anti-platelet drug named clopidogrel. The method of the present invention comprises administration of an (S)oxo-clopidogrel or its derivative of the Formula IIA in its free or pharmaceutically acceptable salt form for alleviating the symptoms of thrombosis or embolism by inhibiting blood platelet aggregation. Compositions for use in such methods are also provided.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: April 26, 2016
    Assignee: IPCA Laboratories Limited
    Inventors: Ashok Kumar, Nellithanath Thankachen Byju
  • Patent number: 9308211
    Abstract: The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.
    Type: Grant
    Filed: May 24, 2014
    Date of Patent: April 12, 2016
    Assignee: Infirst Healthcare Limited
    Inventors: John Brew, Robin Mark Bannister
  • Patent number: 9289438
    Abstract: A method of treating high grade temperature using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: March 22, 2016
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Patent number: 9289440
    Abstract: A method of treating myocardial infarction in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: March 22, 2016
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Patent number: 9289439
    Abstract: A method of reducing hepatocellular damage in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: March 22, 2016
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Patent number: 9271989
    Abstract: The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: March 1, 2016
    Assignee: CMPD LICENSING, LLC
    Inventors: Jay Richard Ray, II, Charles D. Hodge
  • Patent number: 9140703
    Abstract: Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: September 22, 2015
    Assignee: The Cleveland Clinic Foundation
    Inventors: Stanley L. Hazen, Renliang Zhang
  • Patent number: 9056139
    Abstract: The invention provides compositions and methods for treating or preventing cancer with an inventive composition. The invention relates to the fields of biomedicine, pharmacology, and molecular biology.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: June 16, 2015
    Assignee: KEAN UNIVERSITY
    Inventor: Evros Vassiliou
  • Publication number: 20150139973
    Abstract: The present invention relates to an ophthalmological vehicle system for the permeation and/or for the active substance transport of ophthalmological active substances through the cornea and/or the sclera of the eye of mammals. This vehicle system assists the transport of the active substances through the cornea and/or the sclerotic tissue of the eye. The vehicle system is suitable for the prophylaxis and/or treatment of diseases of the front and/or back portion of the eye. Likewise, the present invention relates to an ophthalmological kit, comprising a special ophthalmological composition and also, as separate formulation, an ophthalmological active substance.
    Type: Application
    Filed: May 14, 2013
    Publication date: May 21, 2015
    Inventors: Ute Steinfeld, Frank Holzer, Hyeck Hee Lee, Markus Mahler
  • Publication number: 20150125525
    Abstract: Delayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and the coating comprises an inner layer and an outer layer. The outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria, and a second polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from an at least partially neutralised polycarboxylic acid and a non-ionic polymer. In embodiments in which the third polymeric material is a non-ionic polymer, the inner layer comprises at least one of a buffer agent and a base.
    Type: Application
    Filed: April 29, 2013
    Publication date: May 7, 2015
    Applicant: TILLOTTS PHARMA AG
    Inventors: Roberto Carlos Bravo Gonzalez, Thomas Buser, Frederic Goutte, Abdul Waseh Basit, Felipe Jose, Oliveira Varum, Ana Cristina Freire
  • Patent number: 9023369
    Abstract: The invention relates to freeze-dried molded articles, containing ?50% by wt. of one or more active substances, and ?15% by wt. of one or more scaffold-forming agents, with proteins being excepted, as well as optionally one or more auxiliary substances, in each case based on the total composition of the freeze-dried molded article, whose 1% by wt. solution or suspension in water, at 20° C., has a pH value <7. Furthermore, the invention relates to methods for manufacturing these freeze-dried molded articles, the combination of such freeze-dried molded articles in kit-of-parts arrangements together with aqueous solutions, as well as the use of the freeze-dried molded articles and the kit-of-parts combinations for pharmaceutical and cosmetic application.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: May 5, 2015
    Inventors: Ralf Malessa, Claudia Elsinghorst, Fabian Kuhlmann, Uwe Wagner
  • Publication number: 20150118303
    Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
    Type: Application
    Filed: November 12, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Patent number: 9018193
    Abstract: Novel water stable pharmaceutical compositions, their liquid form oral pharmaceutical compositions and kits thereof, rehydration beverages containing these water stable pharmaceutical compositions methods of manufacture and methods of use thereof are disclosed. The novel aqueous delivery systems are useful, inter alia, as alternative pharmaceutical dosing agents to tablets, capsules and other forms of delivering medication to a mammalian host in need thereof.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: April 28, 2015
    Assignee: Bev-Rx, Inc.
    Inventor: Kyle A. Reed
  • Patent number: 8999961
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: April 7, 2015
    Assignees: Purdue Pharma, L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Publication number: 20150080353
    Abstract: The subject invention relates to compositions and methods useful for the in vivo delivery of substantially water-insoluble drugs, like taxol. The use of specific composition and preparation conditions enables the reproducible production of unusually water-soluble formulation, which can be sterile-filtered. The particulate system produced according to the invention can be converted into a re-dispersible dry powder comprising nanoparticles of drug. The innovation is also based on the fact that complementary partner is also an active drug but may have a different mode action with respect to primary molecule of the hybrid drug. The complementary molecule has multiple properties like antioxidant, antimicrobial, anti-inflammatory, anti-allergic, cox-2 inhibitors, etc. This results in a unique delivery system, in which part of the pharmacologically active agent is readily bioavailable.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 19, 2015
    Inventors: Mewa SINGH, Maninder SANDHU
  • Publication number: 20150072961
    Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
    Type: Application
    Filed: November 14, 2014
    Publication date: March 12, 2015
    Inventors: Chongxi YU, Lina XU
  • Publication number: 20150072005
    Abstract: Provided are methods for enhancing the efficacy of aspirin. Also provided are methods for reducing pain or preventing or treating heart attack, stroke or blood clot in a subject in need thereof. The methods entail orally administering to the subject a first composition comprising a first amount of aspirin, and a second composition comprising a second amount of aspirin, wherein the first composition is formulated so as to, upon administration, disintegrate or dissolve intraorally providing rapid release of the aspirin of the first composition in the subject, and wherein the second composition is formulated to be substantially more difficult than the first composition to disintegrate or dissolve intraorally but is ingestible and releasable in the gastrointestinal track of the subject. The method can further include administering to the subject a painkiller or an agent suitable for treating a cardiovascular disease or condition.
    Type: Application
    Filed: September 10, 2013
    Publication date: March 12, 2015
    Inventor: Joseph P. Habboushe
  • Publication number: 20150051161
    Abstract: The present invention provides compositions and methods for detecting carboxymethyl-lysine (CML) and circulating receptor for advanced glycation end (RAGE) products, and methods for correlating CML and RAGE levels with age-related disease. In particular, serum CML and/or circulating receptor for advanced glycation end (RAGE) products can be used as a clinical biomarker in diagnostics to identify people who are at a higher risk of developing adverse ageing-related outcomes.
    Type: Application
    Filed: April 10, 2014
    Publication date: February 19, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Richard David Semba, Luigi Ferruci, Edward G. Lakatta
  • Publication number: 20140370011
    Abstract: The present invention provides indane acetic acid and their derivatives and methods for the treating and/or preventing of cognitive disorders.
    Type: Application
    Filed: September 4, 2014
    Publication date: December 18, 2014
    Applicant: DARA BIOSCIENCES, INC.
    Inventor: Mary Katherine Delmedico
  • Publication number: 20140356348
    Abstract: Described are methods for diagnosing and predicting the risk of pregnancy loss in a subject based on the presence of an aberrant humoral response to three proteins, Apolipoprotein B-100, alpha2macrogloblin (alpha2M), and fibronectin. The presence or a detectable level of maternal IgG antibodies to trophoblast-derived fibronectin and/or ApoB-100, and/or the absence or a non-detectable level of antibodies specifically binding to alpha2M is associated with a history of RPL and an increased risk of pregnancy loss. Also described are methods for identifying subjects at risk of pregnancy loss, selecting subjects for participation in a clinical study, and methods of decreasing the risk of pregnancy loss in a subject which include detecting the presence or absence of antibodies to one or more of trophoblast-derived ApoB-100, alpha2M, and fibronectin. Also provided are kits that contain ApoB-100, alpha2M, and fibronectin.
    Type: Application
    Filed: May 13, 2014
    Publication date: December 4, 2014
    Applicant: University of Louisville Research Foundation, Inc.
    Inventors: Douglas D. Taylor, Cicek Gercel-Taylor
  • Publication number: 20140348818
    Abstract: Biomarkers of Kawasaki Disease (KD) are provided. In certain aspects, methods are provided for detecting KD biomarkers, such as elevated PDGFC expression. Likewise, methods of treating a subject having a biomarker of KD are described.
    Type: Application
    Filed: December 21, 2012
    Publication date: November 27, 2014
    Inventors: Virginia M. Pascual, Zhaohui Xu, Octavio Ramilo, Rolando Cimaz
  • Publication number: 20140341988
    Abstract: Pharmaceutical dosage forms, particularly dosage forms in granular form having good palatability and capable of rapidly and completely dispersed in the mouth when orally administered.
    Type: Application
    Filed: May 15, 2014
    Publication date: November 20, 2014
    Applicant: APR APPLIED PHARMA RESEARCH SA
    Inventors: Alberto REINER, Giorgio REINER
  • Publication number: 20140335153
    Abstract: A method of preparing a thin film, the method comprising: (a) mixing a lipid, emulsifier, and solvent to provide a uniform first mixture; (b) contacting an active ingredient with the uniform first mixture to provide a thickened second mixture; (c) contacting a binder with the thickened second mixture to provide a slurry; and (d) hot extruding, casting, and condensing the slurry to provide the thin film; or cooling, shearing, mixing, casting, and condensing the slurry to provide the thin film.
    Type: Application
    Filed: October 31, 2013
    Publication date: November 13, 2014
    Applicant: CURE Pharmaceutical Corporation
    Inventors: Eric Allen, Robert Steven Davidson, Jose Bernardo
  • Publication number: 20140329779
    Abstract: The invention discloses a solid transparent vehicle utilizing DBS in which a topical pharmaceutical active or cosmetic active is solubilized without the use of a monohydric and/or polyhydric alcohol thus providing a non-tacky, clear solid, which prevents segregation and insures uniformity in dosing.
    Type: Application
    Filed: January 22, 2013
    Publication date: November 6, 2014
    Applicant: PRODUCT AND TECHNOLOGY PARTNERS LLC
    Inventors: Leonard Mackles, William Bess
  • Publication number: 20140328913
    Abstract: The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms.
    Type: Application
    Filed: July 18, 2014
    Publication date: November 6, 2014
    Inventors: Roger A. Rinker, Nicholas J. Casale, James H. Comly, Brenda Pollack, Johan Geerke, Martin Costello, Dennis Wieand, Kishor Parekh
  • Publication number: 20140322328
    Abstract: The subject technology relates generally to pulmonary delivery of NSAIDs, such as aspirin.
    Type: Application
    Filed: July 24, 2013
    Publication date: October 30, 2014
    Applicant: OtiTopic, Inc.
    Inventor: Kambiz Yadidi
  • Patent number: 8871246
    Abstract: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together with pharmaceutically acceptable carriers suitable for local administration, including those suitable for topical administration. The administration of such compositions provides relief from pain, itching, allodynia, hyperalgesia, and related symptoms.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: October 28, 2014
    Inventor: Lawrence Richard Bernstein
  • Patent number: 8865687
    Abstract: The present invention relates to a preparation suitable for the prevention and/or treatment of vascular disorders, comprising the following fractions: fraction a) consisting of long chain polyunsaturated fatty acids; fraction b) consisting of phospholipids, which fraction contains at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine. fraction c) consisting of compounds which are a factor in methionine metabolism, which fraction contains at least one member selected from the group consisting of folic acid, vitamin B12, vitamin B6, magnesium and zinc.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: October 21, 2014
    Assignee: N.V. Nutricia
    Inventors: Amanda Johanne Kiliaan, Robert Johan Joseph Hageman
  • Publication number: 20140274975
    Abstract: The invention provides methods and compositions for diagnosing prior ischemic stroke or transient ischemic attack (TIA) and approximate the time said stroke occurred, comprising measurement of IgG and IgM antibodies to NR2A and/or NR2B NMDA receptor or fragment thereof in a biological sample, and comparing those measurements to reference population standards and to each other. The invention also includes optionally measuring other biomarkers for autoimmune disease for the reduction in false positives and better risk stratification for future stroke events. The method is particularly useful for identifying individuals that are at risk for future stroke or TIA, and for diagnosing previous history of ischemic stroke or TIA. This measurement and comparison enables determination of the risk of future stroke which is by definition higher in those patients who have suffered a previous stroke.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Health Diagnostic Laboratory, Inc.
    Inventors: Rebecca E. CAFFREY, Mohmed ASHMAIG
  • Patent number: 8834858
    Abstract: The present invention relates to compounds, and compositions, useful for treating dyslipidemia.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: September 16, 2014
    Assignee: Solvotrin Therapeutics Ltd.
    Inventors: Mark Ledwidge, Pat O'Flynn, John Gilmer
  • Publication number: 20140255342
    Abstract: Disclosed is a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the present application.
    Type: Application
    Filed: May 19, 2014
    Publication date: September 11, 2014
    Applicants: TIANJIN HEMAY BIO-TECH CO., LTD., TIANJIN MICHELE SCI-TECH DEVELOPMENT CO., LTD
    Inventors: Hesheng Zhang, Guanghuai Zeng, Yifei Gao
  • Publication number: 20140248352
    Abstract: The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises an enteric coated aspirin active ingredient, and preferably a lightly compressed matrix comprising directly compressible carbohydrate(s) and at least one sweetener.
    Type: Application
    Filed: May 12, 2014
    Publication date: September 4, 2014
    Applicant: MCNEIL-PPC, INC.
    Inventors: Manoj N. Shah, James S. Beahm, Robert Shen
  • Publication number: 20140242153
    Abstract: Disclosed are novel methods for making cochleates and cochleate compositions that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compositions that include an aggregation inhibitor, and optionally, a cargo moiety. Additionally, anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a negatively charge lipid are disclosed. Methods of using the cochleate compositions of the invention, including methods of administration, are also disclosed.
    Type: Application
    Filed: January 30, 2014
    Publication date: August 28, 2014
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Raphael J. Mannino, Susan Gould-Fogerite, Sara L. Krause-Elsmore, David Delmarre, Ruying Lu
  • Publication number: 20140242161
    Abstract: The present invention relates to soft gelatin capsules characterized in that the shell includes a cyclodextrin and in that the filling material contains a liposoluble drug capable of forming a complex with said cyclodextrin for improving the solubility of the active ingredient upon disintegration of the soft gelatin capsule.
    Type: Application
    Filed: April 7, 2014
    Publication date: August 28, 2014
    Inventors: Giorgio ZOPPETTI, Maurizio MARCHIORRI
  • Publication number: 20140234284
    Abstract: The present invention relates to an isocyanate-free multi-component system, in particular for medical uses such as foamable wound coverings, with at least two separate components, wherein the first component comprises at least one alkoxysilane-terminated prepolymer and the second component comprises an aqueous component, wherein the aqueous component is a polyurethane dispersion.
    Type: Application
    Filed: September 24, 2012
    Publication date: August 21, 2014
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Jan Schönberger, Sebastian Dörr